



医渡科技 3 月通讯 | 2026 年

Yidu Tech Events in March 2026

集团亮点

Business Update

文莱卫生部长到访医渡科技及 AI 落地医院

Brunei Minister of Health Visits Yidu Tech and AI-Enabled Hospitals

文莱卫生部部长伊山姆·贾法尔一行到访医渡科技北京总部，并实地考察北京协和医院、北京大学肿瘤医院、清华大学北京清华长庚医院，重点观摩了医渡科技的 AI 中台、医生 Copilot 一系列临床智能体在一线的落地应用，就深化中国与文莱数字健康合作、升级文莱全民健康体系等议题展开深度交流。医渡科技创始人、董事长宫如璟女士携管理团队出席接待。

交流中，医渡科技展示了在医疗数据治理、AI 临床及 AI 医院等方面的核心能力，与文莱在全民健康管理、慢病防控、服务提效等方面的需求高度契合。双方就 BruHealth 平台 AI 升级、智慧医院落地等达成重要合作共识。

A delegation led by Brunei's Minister of Health, Dato Dr Isham Jaafar, visited Yidu Tech's Beijing headquarters and conducted site visits to leading hospitals, including Peking Union Medical College Hospital, Beijing Cancer Hospital, and Beijing Tsinghua Changgung Hospital. The delegation observed firsthand the real-world deployment of Yidu Tech's AI Middleware Platform, Doctor Copilot, and a suite of clinical intelligent agents embedded in frontline medical workflows. In-depth discussions were held on advancing China–Brunei collaboration in digital health and upgrading Brunei's national healthcare system. Yidu Tech's Founder and Chairlady, Gong Rujing, attended the meetings alongside the management team.



During the exchange, Yidu Tech showcased its core capabilities in medical data governance, AI-powered clinical applications, and AI hospital solutions. These capabilities closely align with Brunei's priorities in population health management, chronic disease prevention, and healthcare efficiency enhancement. Both sides reached important consensus on advancing AI upgrades for the BruHealth platform and accelerating the implementation of smart hospital solutions.



印尼卫生部部长到访医渡科技，深化战略合作

Indonesia Minister of Health Visits Yidu Tech to Deepen Strategic Cooperation

印度尼西亚卫生部部长布迪·古纳迪一行到访医渡科技北京总部，就深化中印尼数字健康合作、推动印尼国家医疗体系数字化升级等议题展开了深入交流。交流期间，医渡科技向印尼代表团系统展示了在医疗数据治理、人工智能应用及国家级数字健康平台建设方面的核心能力，并结合印尼在医疗数据整合、医疗服务效率提升及人口健康管理方面的发展需求，重点围绕印尼国家健康数据平台智能化升级、医疗系统 AI 化改造、人口健康管理体系统构建等方向进行了深入探讨，双方就下一步合作计划达成广泛共识。



布迪·古纳迪认为双方合作方向与印尼当前推动医疗体系数字化转型的战略高度契合，期待尽快推动具体项目落地。

A delegation led by Indonesia's Minister of Health, H.E. Budi Gunadi Sadikin, visited Yidu Tech's Beijing headquarters to engage in in-depth discussions on advancing China–Indonesia collaboration in digital health and accelerating the digital transformation of Indonesia's national healthcare system. During the visit, Yidu Tech presented its core capabilities in medical data governance, AI applications, and the development of national-level digital health platforms. In alignment with Indonesia's priorities—including healthcare data integration, service efficiency enhancement, and population health management—the two sides held focused discussions on key areas such as the intelligent upgrade of Indonesia's national health data platform, AI-driven transformation of healthcare systems, and the development of a comprehensive population health management framework. Broad consensus was reached on next-step collaboration plans.

Minister H.E. Budi Gunadi Sadikin noted that the proposed areas of cooperation are highly aligned with Indonesia's current strategy for healthcare digital transformation and expressed strong interest in accelerating the implementation of concrete projects.





医渡科技联合启动中国临床循证智能能力建设计划，医渡智循亮相中关村论坛

**Yidu Tech Co-Launches China's Clinical Evidence Intelligence Initiative;
Yidu Evidence Debuts at ZGC Forum**

2026 中关村论坛年会“世界数字健康论坛”发布一批“医疗科技创新成果”，“中国临床循证智能能力建设计划”作为其重大成果之一在会上正式启动。这是国内首个聚焦循证医学与人工智能深度融合的行业级共建举措。

该计划由清华大学附属北京清华长庚医院等国内多家知名医疗机构共同发起。医渡科技作为该计划核心参与方，承担底层知识建模与 AI 能力输出。该计划核心技术载体——由医渡科技自主研发的临床循证智能体平台“医渡智循”APP 同步上线，面向医生群体开放使用。

At the 2026 ZGC Forum Annual Conference, the "World Digital Health Forum" unveiled a series of "Medical Technology Innovation Achievements," among which the China Clinical Evidence Intelligence Capability Building Initiative was officially launched as a flagship outcome. This marks the first industry-level collaborative effort in China dedicated to the deep integration of evidence-based medicine and artificial intelligence. The initiative is jointly launched by leading medical institutions, including Beijing Tsinghua Changgung Hospital affiliated with Tsinghua University. As a core participant, Yidu Tech is responsible for underlying knowledge modeling and AI capability enablement. The initiative's key technology carrier—the clinical evidence intelligence agent platform "Yidu Evidence", independently developed by Yidu Tech—was also officially launched as an app and is now open to physicians.



医渡科技联合创始人、CEO 徐济铭还受邀参与高端圆桌对话，并重点介绍了“医渡智循”，该产品以医生为中心打造智能循证支撑体系，兼具“超级助手、第二大脑、多学科智能体专家顾问团”的核心角色。在发布前为期一周的内测中，“医渡智循”吸引超 6000 名医疗业内人士踊跃参与，收获近 2000 份优质有效反馈，产品实用性与专业性收获业内高度认可。

Yidu Tech's Co-founder and CEO, Jiming Xu, was also invited to participate in a high-level roundtable discussion, where he highlighted "Yidu Evidence." Designed with physicians at its core, the platform builds an intelligent evidence-based support system that serves as a "super assistant," "second brain," and a multidisciplinary AI expert advisory team. During a one-week pre-launch internal testing phase, "Yidu Evidence" attracted participation from over 6,000 healthcare professionals and collected nearly 2,000 high-quality, actionable feedback submissions. The platform's practicality and professional rigor received strong recognition across the medical community.



医渡科技参加 CMAC 大会，共探 AI 重塑 CRO 新范式

Yidu Tech Participates in CMAC, Exploring How AI is Reshaping the CRO Paradigm

CMAC 创新药物医学大会期间，医渡科技主办的“智启临床，效领未来——AI 重塑 CRO 新范式”学术沙龙成功举行。沙龙由医渡科技生命科学事业部商务副总裁负丽娟主持，苏州大学附属第一医院临床试验机构办张华主任、上海交通大学医学院附属瑞金医院郇京宁主任、扬子江药业集团医药经营总公司医学中心负责人张清睿、医渡科技智能临床研究业务负责人郝原、医渡科技临床试验业务副总裁刘颖等嘉宾出席，与多位来自医疗机构、药企及临床研究领域的代表齐聚一堂，围绕 AI 如何重塑临床研究模式展开深入探讨。

During the CMAC Innovation Drug Development Conference, Yidu Tech successfully hosted an academic salon titled "Empowering Clinical Research, Leading the Future — AI Reshaping the CRO Paradigm." The session was moderated by Lijuan Yun, Vice



President of Business Development for Yidu Tech's Life Sciences division. Distinguished speakers included Director Hua Zhang from the Clinical Trial Office of the First Affiliated Hospital of Soochow University, Director Jingning Huan from Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Qingrui Zhang, Head of the Medical Center at Yangtze River Pharmaceutical Group, Yuan Hao, Head of Intelligent Clinical Research at Yidu Tech, and Ying Liu, Vice President of Clinical Trials at Yidu Tech. Together with representatives from medical institutions, pharmaceutical companies, and the clinical research community, participants engaged in in-depth discussions on how AI is transforming clinical research models and redefining the CRO landscape.



医渡科技亮相深圳 OpenClaw 专题培训，分享 AI 与鸿蒙融合医疗实践

Yidu Tech Showcases AI-HarmonyOS Integration in Healthcare at Shenzhen OpenClaw Training

深入贯彻国家“人工智能+医疗卫生”战略部署，加速推动全市医疗卫生领域数智化转型，以“智联·智驭·智创”为主题的 OpenClaw 技术赋能卫生健康专题培训会在深圳举行。本次会议由深圳市卫生健康发展研究和数据管理中心主办。



医渡科技基础数据技术和架构负责人何威受邀作为分享嘉宾出席本次培训，围绕 OpenClaw 与鸿蒙生态的融合实践，分享了该技术在医疗领域的落地价值与应用场景，为行业提供了可借鉴的实践范本，彰显了医渡科技在前沿 AI 技术应用与医疗数字化转型中的前瞻视野。

To advance China's national "AI + Healthcare" strategy and accelerate digital transformation across the healthcare sector, a themed training session titled "Intelligent Connectivity · Intelligent Control · Intelligent Innovation" was held in Shenzhen, focusing on OpenClaw technology empowerment in healthcare. The event was hosted by the Shenzhen Health Development Research and Data Management Center.

Wei He, Head of Data Infrastructure and Architecture at Yidu Tech, was invited as a keynote speaker. He shared Yidu Tech's practical experience in integrating OpenClaw with the HarmonyOS ecosystem, highlighting real-world applications and value in healthcare scenarios. The session provided actionable insights and replicable models for the industry, underscoring Yidu Tech's forward-looking vision in applying cutting-edge AI technologies to drive healthcare digital transformation.





业务进展

Business Progress

医渡科技携手广西医科大学共建医学人工智能研究院，深化东盟战略布局

Yidu Tech Partners with Guangxi Medical University to Establish Medical AI Institute, Advancing ASEAN Strategy

广西医学人工智能研究院启动暨签约仪式在广西医科大学隆重举行。会上，作为研究院核心理事单位，医渡科技与广西医科大学等多家机构共同签署战略合作协议，将携手共建广西医学人工智能研究院，共同推动“人工智能+医疗卫生”在广西及东盟地区的深度融合与创新发展。此次与广西医科大学达成战略合作，标志着医渡科技在东盟战略布局中再次迈出了实质性一步。

The launch ceremony and signing event for the Guangxi Medical Artificial Intelligence Institute was successfully held at Guangxi Medical University. At the event, Yidu Tech—serving as a core governing member of the institute—signed a strategic cooperation agreement with Guangxi Medical University and other partner institutions to jointly establish the institute and drive the deep integration and innovative development of "AI + Healthcare" across Guangxi and the broader ASEAN region. This strategic partnership marks another significant milestone in Yidu Tech's ASEAN expansion, further strengthening its regional presence and advancing its commitment to building a cross-border AI healthcare ecosystem.



当天，医渡科技、新加坡科技研究局与广西医学人工智能研究院举行了闭门交流会。三方围绕人工智能与医疗卫生深度融合、科研成果转化、国际合作拓展等核心议题展开进一步务实研讨。

On the same day, Yidu Tech, A*STAR, and the Guangxi Medical Artificial Intelligence Institute held a closed-door meeting. The three parties engaged in in-depth and pragmatic discussions on key topics, including the deep integration of artificial intelligence and healthcare, the translation of research outcomes into real-world applications, and the expansion of international collaboration.

医渡科技走进乐城，深化 AI 赋能医疗健康产业合作

Yidu Tech Engages with Lecheng to Deepen AI-Driven Healthcare Industry Collaboration

医渡科技与琼海市、博鳌乐城国际医疗旅游先行区管理局举行交流座谈。琼海市委书记、乐城管理局党委书记周长强，琼海市政府副市长李熙，乐城管理局副局长廖敬乐，琼海市卫健委主任彭时兴等相关部门领导，与医渡科技联合创始人、首席执行官徐济铭，医



渡科技高级副总裁、数据平台业务总经理袁芳等代表齐聚一堂，围绕深化“人工智能+医疗健康”合作、助力琼海现代化产业体系建设进行深入交流。

Yidu Tech held a high-level exchange meeting with Qionghai City and the Boao Lecheng International Medical Tourism Pilot Zone Administration. Key attendees included Zhou Changqiang, Party Secretary of Qionghai Municipal Committee and Secretary of the Party Committee of the Lecheng Administration; Li Xi, Vice Mayor of Qionghai; Liao Jingle, Deputy Director of the Lecheng Administration; and Peng Shixing, Director of the Qionghai Health Commission. They met with Yidu Tech representatives including Co-founder and CEO Xu Jiming and Yuan Fang, Senior Vice President and General Manager of the Data Platform Business.

The discussions focused on deepening collaboration in "AI + Healthcare", supporting the development of Qionghai's modern industrial system, and exploring new pathways for integrating artificial intelligence into healthcare and health industry advancement.





全球首个宫颈癌前病变无创疗法在华获批，医渡科技“AI+全周期管理”助力创新产品普惠可及

World's First Non-Invasive Therapy for Precancerous Cervical Lesions Approved in China; Yidu Tech's "AI + Full-Cycle Management" Enables Accessible Innovation

亚虹医药宣布全球首个针对宫颈上皮内瘤变 2 级 (CIN2) 的非手术无创治疗产品希维她® (APL-1702) 正式获得中国国家药品监督管理局批准上市。这不仅填补了该领域临床治疗的空白，也开启了一个潜力巨大的无创治疗蓝海市场。作为亚虹医药的深度技术合作伙伴，医渡科技依托其旗下核心患者端产品“医渡千愈”与医生端产品“医渡千循”，通过创新的智能化医生-患者一体化服务解决方案，正全力护航这一重磅创新疗法的落地与普及，共同探索宫颈癌前病变诊疗一体化的“中国模式”。

Asieris Pharmaceuticals announced that APL-1702 (Cevira®), the world's first non-surgical, non-invasive treatment for cervical intraepithelial neoplasia grade 2 (CIN2), has been officially approved for market launch by China's National Medical Products Administration (NMPA). This milestone not only fills a critical gap in clinical treatment but also opens up a vast new frontier in non-invasive therapies.

As a key technology partner of Asieris, Yidu Tech leverages its core patient-facing platform "Yidu Qianyu" and physician-facing platform "Yidu Qianxun" to deliver an integrated, AI-powered doctor-patient service solution. Through this innovative "AI + full-cycle management" approach, Yidu Tech is actively supporting the real-world adoption and accessibility of this breakthrough therapy, while jointly exploring a China-driven model for integrated diagnosis and treatment of precancerous cervical lesions.



医渡科技技术赋能，河北医惠保理赔“一站式结算”正式落地

Yidu Tech Empowers Hebei Supplementary Insurance with One-Stop Claims Settlement

河北省普惠型补充医疗保险“河北医惠保”理赔“一站式结算”服务正式上线，实现基本医保与补充医保的出院同步结算。此次服务升级由医渡科技提供技术支撑和业务支持，打通了医保部门与定点医院的结算数据通路，为河北省参保群众带来更便捷、高效的医疗保障体验，也为河北省多层次医疗保障体系建设增添新动能。

The "one-stop settlement" service for Hebei Yihuibao, a provincial supplementary insurance program, has been officially launched. This upgrade enables synchronized settlement of basic medical insurance and supplementary insurance at the point of hospital discharge, significantly improving convenience for insured patients. Powered by Yidu Tech's technical and operational support, the system connects settlement data between healthcare security authorities and designated hospitals, streamlining the claims process. This innovation delivers a more efficient and user-friendly healthcare reimbursement experience for residents across Hebei Province, while adding new momentum to the development of a multi-tiered healthcare security system.

投资者交流

Investor Communication

医渡科技 IRD 受邀参与多场线下策略会及行业论坛，与投资者深入交流 AI 医疗发展趋势与投资逻辑

Yidu Tech IRD Engages in Multiple Strategy Conferences and Industry Forums, Sharing Insights on AI Healthcare Trends and Investment Logic



医渡科技投资者关系总监王晓炜女士近日受邀出席由中信建投证券、广发证券及国泰海通证券等机构举办的多场线下策略会与闭门交流活动，并参与招商证券医药健康创新论坛圆桌讨论，与海内外专业投资机构及产业伙伴围绕 AI 医疗前沿趋势与产业机遇展开深入交流。其中系统介绍了 AI 赋能临床诊疗、科研创新及医药研发等场景的落地进展，并就 AI 驱动下的医疗产业价值重构、商业化路径及长期增长空间与投资者进行了充分探讨。通过多场高质量面对面交流，公司进一步强化了资本市场对其技术能力与战略布局的认知，持续提升在 AI 医疗赛道的专业影响力与市场关注度。

Yidu Tech's IRD, Helena Wang, was recently invited to participate in a series of offline strategy conferences and closed-door meetings hosted by leading institutions including China Securities, GF Securities, and Guotai Haitong Securities. She also joined a roundtable discussion at the China Merchants Securities Healthcare Innovation Forum, engaging with global institutional investors and industry partners on emerging trends and opportunities in AI-driven healthcare.

During these exchanges, Yidu Tech provided a comprehensive overview of its progress in applying AI across clinical care, scientific research, and pharmaceutical R&D. In-depth discussions were also held on how AI is reshaping the healthcare value chain, evolving commercialization pathways, and unlocking long-term growth potential. Through these high-quality, face-to-face engagements, the company further strengthened capital market recognition of its technological capabilities and strategic positioning, while enhancing its professional influence and visibility in the AI healthcare sector.